F. Groves, M. Linet, L. Travis, and S. Devesa, Cancer Surveillance Series: Non-Hodgkin's Lymphoma Incidence by Histologic Subtype in the United States From 1978 Through 1995, JNCI Journal of the National Cancer Institute, vol.92, issue.15, pp.1240-51, 2000.
DOI : 10.1093/jnci/92.15.1240

L. Morton, S. Wang, S. Devesa, P. Hartge, D. Weisenburger et al., Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001, Blood, vol.107, issue.1, pp.265-76, 1992.
DOI : 10.1182/blood-2005-06-2508

S. Horning, Natural history of and therapy for the indolent non-Hodgkin's lymphomas, Semin Oncol, vol.20, issue.5, pp.75-88, 1993.

P. Johnson, A. Rohatiner, J. Whelan, C. Price, S. Love et al., Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center., Journal of Clinical Oncology, vol.13, issue.1, pp.140-147, 1995.
DOI : 10.1200/JCO.1995.13.1.140

H. Schulz, J. Bohlius, S. Trelle, N. Skoetz, M. Reiser et al., Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis, JNCI Journal of the National Cancer Institute, vol.99, issue.9, pp.706-720, 2007.
DOI : 10.1093/jnci/djk152

M. Herold, A. Haas, S. Srock, S. Neser, A. et al., Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study, Journal of Clinical Oncology, vol.25, issue.15, pp.1986-92, 2007.
DOI : 10.1200/JCO.2006.06.4618

W. Hiddemann, M. Kneba, M. Dreyling, N. Schmitz, E. Lengfelder et al., Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group, Blood, vol.106, issue.12, pp.3725-3757, 2005.
DOI : 10.1182/blood-2005-01-0016

R. Marcus, K. Imrie, A. Belch, D. Cunningham, E. Flores et al., CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma, Blood, vol.105, issue.4, pp.1417-1440, 2005.
DOI : 10.1182/blood-2004-08-3175

G. Salles, N. Mounier, S. De-guibert, F. Morschhauser, C. Doyen et al., Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study, Blood, vol.112, issue.13, pp.4824-4855, 2008.
DOI : 10.1182/blood-2008-04-153189

R. Marcus, K. Imrie, P. Solal-celigny, J. Catalano, A. Dmoszynska et al., Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma, Journal of Clinical Oncology, vol.26, issue.28, pp.4579-86, 2008.
DOI : 10.1200/JCO.2007.13.5376

T. Lister, Improved Survival for Patients With Follicular Lymphoma, Journal of Clinical Oncology, vol.23, issue.22, pp.4830-4831, 2005.
DOI : 10.1200/JCO.2005.03.911

Q. Liu, L. Fayad, F. Cabanillas, F. Hagemeister, G. Ayers et al., Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center, Journal of Clinical Oncology, vol.24, issue.10, pp.1582-1591, 2006.
DOI : 10.1200/JCO.2005.03.3696

W. Swenson, J. Wooldridge, C. Lynch, V. Forman-hoffman, E. Chrischilles et al., Improved Survival of Follicular Lymphoma Patients in the United States, Journal of Clinical Oncology, vol.23, issue.22, pp.5019-5045, 2005.
DOI : 10.1200/JCO.2005.04.503

R. Arranz, P. Garcia-alfonso, P. Sobrino, P. Zamora, R. Carrion et al., Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization., Journal of Clinical Oncology, vol.16, issue.4, pp.1538-1584, 1998.
DOI : 10.1200/JCO.1998.16.4.1538

A. Rohatiner, W. Gregory, B. Peterson, E. Borden, P. Solal-celigny et al., Meta-Analysis to Evaluate the Role of Interferon in Follicular Lymphoma, Journal of Clinical Oncology, vol.23, issue.10, pp.2215-2238, 2005.
DOI : 10.1200/JCO.2005.06.146

E. Bachy, P. Brice, R. Delarue, N. Brousse, C. Haioun et al., Long-Term Follow-Up of Patients With Newly Diagnosed Follicular Lymphoma in the Prerituximab Era: Effect of Response Quality on Survival???A Study From the Groupe d'Etude des Lymphomes de l'Adulte, Journal of Clinical Oncology, vol.28, issue.5, pp.822-831, 2010.
DOI : 10.1200/JCO.2009.22.7819
URL : https://hal.archives-ouvertes.fr/hal-00453229

C. Sebban, P. Brice, R. Delarue, C. Haioun, B. Souleau et al., Impact of Rituximab and/or High-Dose Therapy With Autotransplant at Time of Relapse in Patients With Follicular Lymphoma: A GELA Study, Journal of Clinical Oncology, vol.26, issue.21, pp.3614-3634, 2008.
DOI : 10.1200/JCO.2007.15.5358

P. Solal-celigny, E. Lepage, N. Brousse, F. Reyes, C. Haioun et al., Recombinant Interferon Alfa-2b Combined with a Regimen Containing Doxorubicin in Patients with Advanced Follicular Lymphoma, New England Journal of Medicine, vol.329, issue.22, pp.1608-1622, 1993.
DOI : 10.1056/NEJM199311253292203

P. Solal-celigny, E. Lepage, N. Brousse, C. Tendler, P. Brice et al., Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial., Journal of Clinical Oncology, vol.16, issue.7, pp.2332-2340, 1998.
DOI : 10.1200/JCO.1998.16.7.2332

E. Kaplan and P. Meier, Nonparametric Estimation from Incomplete Observations, Journal of the American Statistical Association, vol.37, issue.282, pp.457-81, 1958.
DOI : 10.1214/aoms/1177731566

D. Cox, Regression Models and Life-Tables, J Royal Stat Soc Series B, vol.34, pp.187-220, 1972.
DOI : 10.1007/978-1-4612-4380-9_37

P. Solal-celigny, P. Roy, P. Colombat, J. White, J. Armitage et al., Follicular Lymphoma International Prognostic Index, Blood, vol.104, issue.5, pp.1258-65, 2004.
DOI : 10.1182/blood-2003-12-4434
URL : https://hal.archives-ouvertes.fr/hal-00427653

H. Hochster, E. Weller, R. Gascoyne, T. Habermann, L. Gordon et al., Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study, Journal of Clinical Oncology, vol.27, issue.10, pp.1607-1621, 2009.
DOI : 10.1200/JCO.2008.17.1561

L. Gouill, S. , D. Guibert, S. Planche, L. Brice et al., Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study, Haematologica, vol.96, issue.8, pp.1128-1163, 2011.
DOI : 10.3324/haematol.2010.030320

D. Carney, D. Westerman, C. Tam, A. Milner, H. Prince et al., Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy, Leukemia, vol.2, issue.12, pp.2056-62, 2010.
DOI : 10.1016/S1470-2045(09)70003-8

E. Gyan, C. Foussard, P. Bertrand, P. Michenet, L. Gouill et al., High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years, Blood, vol.113, issue.5, pp.995-1001, 2009.
DOI : 10.1182/blood-2008-05-160200

K. Carson, A. Evens, E. Richey, T. Habermann, D. Focosi et al., Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project, Blood, vol.113, issue.20, pp.4834-4874, 2009.
DOI : 10.1182/blood-2008-10-186999